Home

Andy Pasternak

CIK 1792746 · Chief Strategy Officer · last filed 2026-06-26

Andy Pasternak is a Chief Strategy Officer who has filed 25 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for CNTX, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$13.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.5M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.47M

Companies

3

Total Filings

25

Lifetime Open-Market Net

-$13.92M

Filer Profile

Reported Address
2001 MARKET STREET
SUITE 3915, UNIT 15
PHILADELPHIA, PA 19103
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CNTX Director — $0.35 — $0 3 2026-06-26
KARD Chief Strategy Officer 79,640 $18.52 $1.47M $0 1 2026-06-22
Horizon Therapeutics Public Ltd Co (HZNP) Delisted EVP, Chief Strategy Officer 0 $116.30 $0 -$13.92M 21 2023-10-06

Recent Filings

25 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 CNTX Grant (A) — $0 EDGAR
2026-06-22 KARD Grant (A) +79,640 $0 EDGAR
2025-06-12 CNTX Grant (A) — $0 EDGAR
2025-01-14 CNTX Grant (A) — $0 EDGAR
2023-10-06 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Disp (D) −56,338 -$6.56M EDGAR
2023-01-18 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Sell (S) −27,129 -$3.07M EDGAR
2023-01-06 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Grant (A) — $0 EDGAR
2023-01-04 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Mixed +49,420 -$4.47M EDGAR
2022-12-29 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Grant (A) — $0 EDGAR
2022-12-14 Horizon Therapeutics Public Ltd Co (HZNP) Delisted Mixed −6,918 -$2.71M EDGAR
Showing 1–10 of 25
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.